Parecoxib 200 mg | Purity Not Available
TargetMol
Parecoxib
Search Results
Parecoxib 10 mg | Purity Not Available
TargetMol
Parecoxib
AT7519 Hydrochloride 25 mg | 99.88%
TargetMol
AT7519 hydrochloride is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9.
More Information Supplier PageAT7519 Hydrochloride
AT7519 Hydrochloride 10 mg | 99.88%
TargetMol
AT7519 hydrochloride is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9.
More Information Supplier PageAT7519 Hydrochloride
Empagliflozin 200 mg | 99.89%
TargetMol
Empagliflozin is a Sodium-Glucose Cotransporter 2 Inhibitor. The mechanism of action of empagliflozin is as a Sodium-Glucose Transporter 2 Inhibitor.
More Information Supplier PageEmpagliflozin
Obeticholic Acid 200 mg | 99.78%
TargetMol
Obeticholic Acid (6-ECDCA) is a Farnesoid X Receptor Agonist. The mechanism of action of obeticholic acid is as a Farnesoid X Receptor Agonist.
More Information Supplier PageObeticholic Acid
Clemizole hydrochloride 25 mg | 99.91%
TargetMol
Clemizole hydrochloride is an antagonist for H1 histamine receptor. According to the research, Clemizole hydrochloride can inhibit hepatitis C virus (HCV) replication and NS4B’s RNA binding.
More Information Supplier PageClemizole hydrochloride
LDN-57444 50 mg | 97.80%
TargetMol
LDN-57444 is a reversible, competitive proteasome Uch-L1 inhibitor(IC50=0.88 μM) .
More Information Supplier PageLDN-57444
LDN-57444 5 mg | 97.80%
TargetMol
LDN-57444 is a reversible, competitive proteasome Uch-L1 inhibitor(IC50=0.88 μM) .
More Information Supplier PageLDN-57444
GSK 3 Inhibitor IX 100 mg | 99.90%
TargetMol
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.
More Information Supplier PageGSK 3 Inhibitor IX
